FDA Launches Commissioner’s National Priority Voucher To Expedite Drug Reviews 
By

By
The US Food and Drug Administration has launched a new priority review voucher with the goal of reducing the agency’s drug review times to 1 to 2 months for certain…

Lilly To Acquire Verve Therapeutics in $1.3-Bn Deal 
By

By
Eli Lilly and Company has agreed to acquire Verve Therapeutics, a Boston-based clinical-stage bio/pharmaceutical company developing genetic medicines for cardiovascular disease, in a deal worth up to $1.3 billion ($1…

Supplier News: Cytiva, Veranova, Delpharm & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Veranova, Cytiva, Enzene, Kindeva, Delpharm, ReciBioPharm, Tjoapack and Tekniplex.   Chemicals/Chemical API Manufacturing * Veranova Breaks Ground on New ADC Mfg Facility; Adding Bioconjugation…

Partnering News: AstraZeneca, Regeneron, Teva & More 
By

By
A roundup of bio/pharmaceutical partnering news from AstraZeneca/CSPC, Regeneron/Hansoh Pharma, Teva/Fosun Pharma, GSK/Bharat Biotech, and Astellas/Mitsubishi Research Institute.  * AstraZeneca, China’s CSPC in $5.3-Bn AI Drug-Development Pact* Regeneron, Hanosh Pharma…

M&A News: Supernus, Regeneron & More 
By

By
The latest news on mergers and acquisitions featuring. Highlights below.  * Supernus Pharma to Acquire Sage Therapeutics in $795-M Deal * Regeneron Outbid for Genetic Testing Company 23andMe  Supernus Pharma to…

BMS, BioNTech in $11-Bn Oncology Drug Pact  
By

By
Bristol Myers Squibb (BMS) and BioNTech, a Mainz-Germany-based bio/pharmaceutical company, have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody, BNT327, across numerous solid…

UCB Investing in New US Biomanufacturing Facility  
By

By
UCB, a Brussels, Belgium-based bio/pharmaceutical company, has announced plans to build a new US-based biomanufacturing facility and to scale up its partnerships with US-based CDMOs.   The company says that the…

BioNTech To Acquire CureVac for $1.25 Bn 
By

By
BioNTech, a Mainz, Germany-based bio/pharmaceutical company, has agreed to acquire CureVac, a Tubingen, Germany-based clinical-stage bio/pharmaceutical company specializing in mRNA cancer immunotherapies and vaccines, for $1.25 billion.   With the acquisition,…

Supplier News: WuXi Biologics, Resilience, Carbogen Amics, Simtra & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Euroapi, Simtra BioPharma Solutions, MilliporeSigma, Made Scientific, PharmaLogic, Fujifilm, Antheia, Carbogen Amcis, Cellares, Mitsui, Schott Pharma and DuPont.   Chemicals/Chemical API…

Partnering News: Astellas, Lilly, Novo Nordisk & More 
By

By
A roundup of bio/pharmaceutical partnering news from Astellas/Evopoint Biosciences, Eli Lilly and Company/Camurus, Novo Nordisk/Deep Apple Therapeutics and Eli Lilly and Company/Juneva.  * Astellas, Evopoint Biosciences in $1.54-Bn ADC Pact *…